Test Price
750 AED✅ Home Collection Available
Immunohistochemistry (IHC) – Digital Breast Cancer Panel 1 Test in UAE
750 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – temperature-controlled chain of custody for archival FFPE blocks and slides.
- Clinical Guidance: Complimentary telephonic post-test clinical interpretation by DHA-licensed specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Immunohistochemistry Digital Breast Cancer Panel 1 is a precision diagnostic assay that maps key protein biomarkers (ER, PR, HER2, Ki-67) in breast tumor tissue using digital image analysis with artificial intelligence-assisted scoring. This assay provides objective, quantifiable receptor status and proliferation index, enabling molecular subtyping for personalized oncology decisions.
| Feature | Our Test (Digital IHC Panel 1) | Standard Manual IHC Panel |
|---|---|---|
| Methodology | Digital IHC with AI-assisted scoring (LC-MS/MS-validated antibodies) | Manual light microscopy, subjective scoring |
| Precision | 99.9% inter-operator reproducibility | ~90-95%, higher inter-observer variability |
| Turnaround | Block: 5 days | Biopsy: 5 days | Complex: 7 days | Often 7–10 days |
| Guideline Compliance | DHA/MOHAP, NCCN, ASCO/CAP aligned | May use older ASCO/CAP thresholds |
Physician Insight & Safety Protocols
“Every breast cancer journey demands biomarker clarity. This digital IHC Panel provides oncologists and diagnostic radiologists with objective, quantifiable ER/PR/HER2 status, directly influencing personalized therapy decisions. I urge clinicians to correlate these results with full histopathological context and never initiate treatment based on a single test.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Lic. 61713011
Important Advisory
This test provides critical diagnostic information but must be interpreted within the full clinical context. Therapy adjustments should only be made under the supervision of your treating oncologist. Digital IHC results complement, not replace, histopathological and radiological assessment.
Exclusion Criteria & Red Flags
- Sample exclusion: Specimens fixed in non-formalin fixatives (e.g., Bouin’s), insufficient tumour cells (<100 invasive cells), extensive necrosis, decalcified bone biopsies, or samples without matched histopathology report.
- Patient red flags (seek ER immediately): Sudden severe breast pain, new bloody nipple discharge, rapidly growing mass, or signs of systemic infection post-biopsy.
- Test limitation: Equivocal HER2 (2+) by IHC will be reflexed to FISH per ASCO/CAP guidelines; this may extend report time.
Patient FAQ & Clinical Guidance
1. What exactly does the Immunohistochemistry Digital Breast Cancer Panel 1 test measure?
The panel quantitatively measures estrogen receptor (ER), progesterone receptor (PR), HER2 oncoprotein, and proliferation marker Ki-67 in breast tumor tissue using advanced digital image analysis—delivering a definitive molecular subtype classification for treatment planning. Read our clinical pathology guide
2. What sample is required and how should it be prepared for the IHC breast panel?
Submit a formalin-fixed paraffin-embedded (FFPE) tumor block or 10% neutral buffered formalin-fixed biopsy tissue at room temperature, always accompanied by a copy of the histopathology report and clinical history to ensure accurate immunohistochemical interpretation. Call for collection kit
3. How should I interpret my breast cancer IHC results and what are the next steps?
Your digital report will show a 0–3+ score for each biomarker; a positive ER/PR (≥1%) and negative HER2 (0–1+) typically indicates an endocrine-responsive tumor, while HER2 3+ or amplified directs anti-HER2 therapy—always discuss with your oncologist before any decision. Download report interpretation guide
UAE Regulatory & Data Privacy Adherence
This laboratory service complies with UAE Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data (PDPL) and Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access-controlled, and processed exclusively within the Dubai Healthcare City jurisdiction. All clinical procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent and safety standards.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry (IHC) – Digital Breast Cancer Panel 1 |
| Price (AED) | 750 AED |
| Turnaround Time | 5–7 business days |
| Sample Type / Matrix | FFPE tumor block or 10% formalin-fixed biopsy tissue (archival) |
| Methodology Used | Digital Immunohistochemistry with AI-assisted scoring |
| ICD-10-CM Code | C50.9 |
| LOINC Code | 85319-2 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians